Screening for azathioprine toxicity: A pharmacoeconomic analysis based on a target case
- 1 April 2000
- journal article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 42 (4) , 628-632
- https://doi.org/10.1016/s0190-9622(00)90176-2
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- IMMUNOSUPPRESSIVE AGENTS IN DERMATOLOGYDermatologic Clinics, 1998
- Annual Trainee Awards for 1996 and 1997Archives of Dermatology, 1998
- Azathioprine‐induced severe pancytopenia due to a homozygous two‐point mutation of the thiopurine methyltransferase gene in a patient with juvenile HLA‐B27‐associated spondylarthritisArthritis & Rheumatism, 1997
- Human thiopurine methyltransferase pharmacogenetics: Gene sequence polymorphisms*Clinical Pharmacology & Therapeutics, 1997
- Azathioprine in dermatology: a survey of current practice in the U.K.British Journal of Dermatology, 1997
- A pharmacogenetic basis for the safe and effective use of azathioprine and other thiopurine drugs in dermatologic patientsJournal of the American Academy of Dermatology, 1995
- Azathioprine-related bone marrow toxicity and low activities of purine enzymes in patients with rheumatoid arthritisArthritis & Rheumatism, 1995
- Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience.Gut, 1993
- THE IMPORTANCE OF THIOPURINE METHYLTRANSFERASE ACTIVITY FOR THE USE OF AZATHIOPRINE IN TRANSPLANT RECIPIENTS1Transplantation, 1992
- Pharmacogenetics of acute azathioprine toxicity: Relationship to thiopurine methyltransferase genetic polymorphismClinical Pharmacology & Therapeutics, 1989